I joined the Health Economics Research Centre in January 2003 and developed a research programme on the economics of genetic and genomic technologies. Of particular interest are the economics of translating high-throughput sequencing technologies such as whole genome sequencing in rare diseases and cancer into health care systems.

My other research interests include antimicrobial resistance (AMR) where I explore the contribution that health economics can bring to this important health area and identify barriers to implementing interventions for reducing AMR. I also address methodological challenges in trial based economic evaluations in the areas of surgery for obesity, lung cancer surgery, cardiovascular disease and eye disease.